Published 10/24/22; updated 11/3/22
Summary
The 64th annual American Society of Hematology meeting takes place from December 10-13, 2022 online and in person at the Ernest N. Morial Convention Center in New Orleans, Louisiana
This meeting features the newest advances in hematology and is the world’s premier event in malignant and non-malignant hematology
Abstracts are being released November 3rd at 9am EST (late breaking abstracts to be released November 22) at which time many smid-cap biopharma companies followed by BPIQ are likely to announce their involvement
See our forum post HERE and watch for many hematology companies announcing their involvement in the next few weeks after subscribing. Learn more here.
Abstracts released today November 3! See Table 1 for tickers, abstract links, and prelim info on the trials to be presented. See our forum for more info!
The American Society of Hematology (ASH) 2022 annual meeting will take place from December 10-13, 2022 online and in person. Browse the full ASH2022 program HERE.
Every year, upon abstract release and as a result of presentations at the conference, some biopharma stocks move significantly because they report important clinical trial updates. Abstracts for regular presentations at ASH22 will be released November 3 at 9am EST and late breaking abstracts will be released November 22. We will continue to keep this post and our forum updated as companies begin to announce their involvement and publish their abstracts. Take a look at our 2021 ASH forum for an idea of companies that may present this year. Also check out our catalyst calendar where you can search for hematology companies.
Want to get Catalyst Events and stocks to watch sent directly to your inbox each week? sign up for our free weekly newsletter
Positive clinical trial results in a single trial can have a significant impact on the underlying stock price. This is especially true for biopharma companies with market caps under $5 billion, who typically have far less clinical and approved assets than larger companies, and thus whose valuation can be more affected by a single drug candidate and trial. The clinical assets of these micro, small and mid-cap cancer biopharma companies are a primary driver for the development of future blood disease therapies.
To this end, our team will watch for abstracts to be released and scour the press releases to determine which smid-cap biopharmas are presenting new clinical data. Watch for abstracts to be released November 3rd! And watch for additional blog posts for other exciting conferences this year in kidney disease, liver disease, and Alzheimer's disease.
The question for biopharma investors now with respect to ASH2022 is which stocks or groups of stocks are likely to move upon the release of the ASH abstract, poster, oral presentation, or associated investor meeting. We plan to continue to analyze ASH22 companies as well as the abstracts, once released, and plan to update this information on BPIQ.com. In the meantime, watch for updates to this article to see smid-cap biopharma companies that are developing some of our most exciting future medicines. For investors, these companies represent an exciting opportunity for further diligence and possible investment.
Table 1. Smid-cap biopharmas presenting clinical data at ASH 2022
See our BPIQ forum post for a more in depth table after subscribing. Learn more here.
This article is NOT legal, investment or tax advice. Please do your own diligence before making any investments.
Article history:
Originally posted 10/24/22
If you are serious about investing in biotech stocks BPIQ is the research companion that will take you to the next level.
Save yourself time by accessing our database of over 550 companies, 1,800+ of their drug assets, and tools including: Catalyst Calendar, Big Movers, Company Pipelines, and more!
P.S. We are currently running a sale - lock in the price before it's gone
See what our members are saying about us:
Mike from United States
“Really loving the site over the competitor... like the layout and speed over the competition...like the individual pages for each drug/treatment”
Carl from United States
“I like your service. I haven’t seen anyone else doing something similar...nothing like this available for retail.”
Essey from Canada
“Love what you’re doing, this website is awesome.”
James from United States
Great site and I see it’s a family run business, great job.”
Comments